Search results for "Receptor"

showing 10 items of 6990 documents

2021

White adipose tissue (WAT) possesses the endocannabinoid system (ECS) machinery and produces the two major endocannabinoids (ECs), arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG). Accumulating evidence indicates that WAT cannabinoid 1 receptors (CB1R) are involved in the regulation of fat storage, tissue remodeling and secretory functions but their role in controlling lipid mobilization is unclear. In the present study, we used different strategies to acutely increase ECS activity in WAT and tested the consequences on glycerol production as a marker of lipolysis. Treating lean mice or rat WAT explants with JLZ195, which inhibits ECs degrading enzymes, induced an increase in…

medicine.medical_specialtyChemistryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipose tissueStimulationWhite adipose tissueEndocannabinoid systemEndocrinologyRimonabantInternal medicinemedicineLipolysislipids (amino acids peptides and proteins)CannabinoidReceptormedicine.drugFrontiers in Endocrinology
researchProduct

Role of IP3 Receptors in Shaping the Carotid Chemoreceptor Response to Hypoxia But Not to Hypercapnia in the Rat Carotid Body: An Evidence Review

2020

This article addresses the disparity in the transduction pathways for hypoxic and hypercapnic stimuli in carotid body glomus cells. We investigated and reviewed the experimental evidence showing that the response to hypoxia, but not to hypercapnia, is mediated by 1,4,5-inositol triphosphate receptors (IP3R/s) regulating the intracellular calcium content [Ca2+]c in glomus cells. The rationale was based on the past observations that inhibition of oxidative phosphorylation leads to the explicit inhibition of the hypoxic chemoreflex. [Ca2+]c changes were measured using cellular Ca2+-sensitive fluorescent probes, and carotid sinus nerve (CSN) sensory discharge was recorded with bipolar electrode…

medicine.medical_specialtyChemistryInositol trisphosphate receptorHypoxia (medical)Calcium in biologymedicine.anatomical_structureGlomus cellEndocrinologyInternal medicinemedicineCarotid bodymedicine.symptomReceptorHypercapniaIntracellular
researchProduct

Chapter 21 Modulation of acetylcholine release by nitric oxide

1996

Publisher Summary This chapter reviews the studies in which the effects of endogenous and exogenous nitric oxide (NO) on the release of acetylcholine were investigated. As tools for the involvement of endogenous NO, the effects of NO synthase inhibitors on release of acetylcholine were studied. The cholinergic neurons are tonically stimulated by endogenous NO. On the other hand, NO synthase inhibitors fail to change either basal or electrically evoked acetylcholine release from slices of rat hippocampus and striatum. Endogenous and exogenous NO increase basal acetylcholine release from central and peripheral cholinergic neurons. The effect is tetrodotoxin sensitive and calcium-dependent, th…

medicine.medical_specialtyChemistryMuscarinic acetylcholine receptor M3PharmacologyNitroargininechemistry.chemical_compoundEndocrinologyInternal medicineMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptorMuscarinic acetylcholine receptor M4medicineCholinergicCholinergic neuronAcetylcholinemedicine.drug
researchProduct

Diminished Inhibition of Adhesion Molecule Expression in Prostacyclin Receptor Desensitized Human Platelets

1995

Long-term exposure of platelets to prostacyclin or iloprost (100nM, 3hr) results in receptor desensitization measured as decrease in 3H-iloprost binding sites by 47 +/- 14%. Desensitized platelets respond with an increased adhesion to endothelial cells. The mechanism of increased adhesiveness was studied by measuring the expression of the adhesion molecule CD62p (p-selectin; GMP140) on washed human platelets by flowcytometry. In thrombin stimulated platelets CD62p expression was dose-dependently reduced by iloprost. In receptor desensitized platelets IC50 for iloprost inhibition of thrombin-induced CD62p expression increased from 0.48 +/- 0.10 to 2.4 +/- 0.7 nM.

medicine.medical_specialtyChemistryProstacyclinAdhesionThrombinEndocrinologyInternal medicinecardiovascular systemmedicinelipids (amino acids peptides and proteins)PlateletReceptorProstacyclin receptorIC50circulatory and respiratory physiologyIloprostmedicine.drug
researchProduct

Human Prostate Cancer: A Direct Role for Oestrogens

2007

We have studied the response to oestrogen and expression of oestrogen receptors in responsive LNCaP and androgen non-responsive PC3 human prostate cancer cell lines. Growth of LNCaP cells is significantly stimulated by physiological concentrations of oestradiol; this growth increase appears to be comparable to that induced by either testosterone or dihydrotestosterone. In contrast, oestradiol significantly inhibits the proliferation of PC3 cells. We also present novel evidence for functional oestrogen binding in LNCaP cells. This evidence was first obtained by means of radioligand binding assays and was further corroborated using: (a) immunocytochemical analysis of oestrogen and progesteron…

medicine.medical_specialtyChemistrymedicine.drug_classurologic and male genital diseasesmedicine.diseaseAndrogenProstate cancerchemistry.chemical_compoundEndocrinologyInternal medicineDihydrotestosteroneLNCaPmedicineGrowth inhibitionskin and connective tissue diseasesReceptorTestosteroneTransforming growth factormedicine.drug
researchProduct

Behandlung der ausgeprägten Pubertätsgynäkomastie mit Tamoxifen

1987

Based on the good results of another author 10 boys with marked pubertal gynecomastia were treated with the antioestrogen Tamoxifen (Nolvadex) at a dose of 20-40 mg/d orally for 2-12 months. In most cases the gynecomastia decreased totally, only two patients experienced palpable subareolar glandular tissue at the end of therapy. Side effects were not noted. During therapy levels of estradiol and testosteron increased, with a more pronounced elevation of estradiol. Basal values of LH and FSH remained nearly unchanged, but LH showed an increased response to LH-RH, which could be explained by the antioestrogenic effect of Tamoxifen at the hypothalamic level. The reduction of breast size in spi…

medicine.medical_specialtyChemotherapyEnd of therapybusiness.industrymedicine.medical_treatmentTherapeutic effectEstrogen receptormedicine.diseaseBlockadeBasal (phylogenetics)EndocrinologyGynecomastiaInternal medicinePediatrics Perinatology and Child Healthmedicineskin and connective tissue diseasesbusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugKlinische Pädiatrie
researchProduct

Differences in zinc status and the leptin axis in anorexic and recovered adolescents and young adults : a pilot study

2012

Food & nutrition research 56, 8 S. (2012). doi:10.3402/fnr.v56i0.10941

medicine.medical_specialtyChild and Adolescent Psychiatry; Medicine;lcsh:TX341-641leptin receptor (sOB-R)leptinanorexia nervosaInternal medicineMedicineddc:610Young adultResearch dataNutrition and DieteticsLeptin receptorbusiness.industryAnorexia nervosa; leptin; leptin receptor (sOB-R); free leptin index (FLI); zincLeptinzincfungidigestive oral and skin physiologyPublic Health Environmental and Occupational HealthControl subjectsfree leptin index (FLI)EndocrinologyAnorexia nervosa (differential diagnoses)Eating disordersOriginal ArticleAnimal studiesNutrition researchbusinesslcsh:Nutrition. Foods and food supplyhormones hormone substitutes and hormone antagonistsFood Science
researchProduct

Anti-androgens for the treatment of hirsutism.

2002

Many alternatives exist for treating hirsutism. Based on an analysis of scientific literature and on the experiences of the author, the most common anti-androgen agents are discussed in this review. Androgen receptor blockers (cyproterone acetate, flutamide and spironolactone), 5 alpha-reductase inhibitors (finasteride) and androgen-suppressing agents (gonadotrophin-releasing hormone [GnRH] agonists, oestroprogestins, corticosteroids and insulin-sensitising agents) are evaluated and compared. The importance of diagnosis in choosing the most appropriate anti-androgen treatment is also discussed.

medicine.medical_specialtyCholestenone 5 alpha-ReductaseHirsutismAnti-Androgenurologic and male genital diseasesFlutamideGonadotropin-Releasing Hormonechemistry.chemical_compoundInternal medicineAndrogen Receptor AntagonistsMedicineHumansPharmacology (medical)Androgen Receptor AntagonistshirsutismPharmacologybusiness.industryCyproterone acetateAndrogen AntagonistsGeneral Medicinemedicine.diseaseAndrogen receptorEndocrinologyTreatment OutcomechemistrySpironolactoneFinasterideAndrogensFemalebusinessOxidoreductasesExpert opinion on investigational drugs
researchProduct

Getting the Fat out of Met and Fas

2008

Lack of Fas antagonism by Met in human fatty liver disease. Zou C, Ma J, Wang X, Guo L, Zhu Z, Stoops J, Eaker AE, Johnson CJ, Strom S, Michalopoulos GK, DeFrances MC, Zarnegar R. Hepatocytes in fatty livers are hypersensitive to apoptosis and undergo escalated apoptotic activity via death receptor-mediated pathways, particularly that of Fas–FasL, causing hepatic injury that can eventually proceed to cirrhosis and end-stage liver disease. Here we report that the hepatocyte growth factor receptor, Met, plays an important part in preventing Fas-mediated apoptosis of hepatocytes by sequestering Fas. We also show that Fas antagonism by Met is abrogated in human fatty liver disease (FLD). Throug…

medicine.medical_specialtyCirrhosisHepatologyFatty liverBiologymedicine.diseaseMolecular biologyFas ligandLiver diseaseEndocrinologyHepatocyte Growth Factor ReceptorApoptosisInternal medicinemedicineExtracellularAntagonismJournal of Hepatology
researchProduct

Erythropoietin in Traumatic Brain Injury: An Answer Will Come Soon

2015

Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. It is estimated that each year TBIs are associated with 1.1 million emergency department visits, 235,000 hospitalizations, and 50,000 deaths (1). Despite improvements in medical interventions, there are still no neuroprotective agents available to counteract secondary or delayed damage to the traumatically injured human brain or to promote its repair. TBI encompasses heterogeneous etiologic, anatomical, and molecular patterns of injury that exhibit different propensities to cause cerebral damage. Without careful consideration of individual injuries, the results of therapeutic trials remain difficu…

medicine.medical_specialtyClinical Trials as Topicbusiness.industryTraumatic brain injurySettore MED/27 - NeurochirurgiaMedicine (all)Neuroprotective AgentRecombinant Proteinmedicine.diseaseRecombinant ProteinsEpoetin AlfaNeuroprotective AgentsErythropoietinBrain InjuriesBrain InjurieReceptors ErythropoietinMedicineHumansSurgeryNeurology (clinical)businessIntensive care medicineErythropoietinmedicine.drugHuman
researchProduct